Company news
Bioxyne Limited (ASX:BXN) news
Bioxyne Limited news releases on 6ix. Latest, May 21, 2026: Notice of General Meeting/Proxy Form
Press releases & updates
Notice of General Meeting/Proxy Form
May 21, 2026
Secures $50m Exclusive German Supply Agreement with ADREX
May 11, 2026
Expands LATAM Footprint First Supply Agreement Costa Rica
May 10, 2026
Manufacturing Agreement Aurora Supplementary Information
March 31, 2026
Bioxyne Signs Manufacturing Agreement with Aurora Cannabis
March 31, 2026
BXN H1 FY2026 Results Presentation
February 25, 2026
Stronger H1 FY2026 Performance Upward Revision to Guidance
February 25, 2026
Half Yearly Report and Accounts
February 25, 2026
Presentation Results Q2 FY2026
January 29, 2026
Appendix 4C Revised
January 27, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 27, 2026
Supply Agreement Secured - Central American Cannabis Markets
December 10, 2025
Funding from SOSE to Establish UK GMP Manufacturing Facility
November 16, 2025
BLS to Manufacture and Distribute Curaleaf International MID
November 2, 2025
Presentation on FY2025 Quarter 1 Results
October 30, 2025
Initial German Purchase Orders and Import Permits
September 14, 2025
BXN Full Year 2026 Guidance
August 29, 2025
FY2025 Results Presentation
August 29, 2025
Preliminary Final Report
August 29, 2025
30 June 2025 Appendix 4C Revised
August 18, 2025
Bioxyne Updated Investor Presentation
July 28, 2025
Investor Presentation Update
June 19, 2025
Enters German Market Euro3.2m Manufacturing & Supply Agmt
June 17, 2025
Certificate GMP Compliance EU, UK, Singapore & Canada
June 17, 2025
FY25 Revenue Guidance Upgrade
June 11, 2025
BXN Signs Exclusive $7m Manufacturing and Supply Agreement
April 2, 2025
Bioxyne Raises A$3 million in Capital Raise
March 20, 2025
Trading Halt
March 18, 2025
Pause in Trading
March 18, 2025
BXN H1 FY25 Results Presentation
February 27, 2025
Quarterly Activities Report December 2024 Revised
January 27, 2025
Revenue Guidance
January 23, 2025
Addendum to Presentation dated 18 November 2024
January 13, 2025
Response to ASX Price Query
November 28, 2024
Investor Presentation November 2024
November 18, 2024
Bioxyne Extends Contract with Aura Therapeutics
September 23, 2024
Response to ASX Aware Query
September 18, 2024
Reinstatement to Quotation
September 17, 2024
Announcement 21.8.2024 Clarifying Statement
September 17, 2024
Suspension from Official Quotation
September 13, 2024
Response to ASX Query Letter
August 23, 2024
BXN Manufactures First Pharmaceutical Cannabis Gummies
August 20, 2024
BXN Awarded GMP Manufacturing License for Medical Cannabis
February 4, 2024
Retirement of Director
November 17, 2023
BLS Extends Amazon Footprint into US and Japan
July 17, 2023
BXN to Acquire Health & Wellness Co Breathe Life Sciences
December 18, 2022
Joins Asian Partner & Sells 49% of Direct Selling Business
October 23, 2022
Appendix 4D and Interim Report
February 22, 2022
Bioxyne : Appendix 4D and Interim Report
February 21, 2022
Reinstatement to Official Quotation
November 3, 2021